TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years
Brief Summary: This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.


Options:
A: Arm Label: Group 1: Guan-Guan+Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guanfacine | Arm Label: Group 2: Placebo-Placebo+DMPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (MPH) | Arm Label: Group 3: Guan-Guan+DMPH (Comb); Type: EXPERIMENTAL; Interventions: Drug: Guanfacine, Drug: Methylphenidate (MPH) | Intervention Type: DRUG; Name: Guanfacine; Assigned to Arm(s): Group 1: Guan-Guan+Placebo, Group 3: Guan-Guan+DMPH (Comb) | Intervention Type: DRUG; Name: Methylphenidate (MPH); Assigned to Arm(s): Group 2: Placebo-Placebo+DMPH, Group 3: Guan-Guan+DMPH (Comb)
B: Arm Label: NT0102; Type: EXPERIMENTAL; Interventions: Drug: NT0102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NT0102; Assigned to Arm(s): NT0102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Focalin XR then Adderall XR; Type: EXPERIMENTAL; Interventions: Drug: Dexmethylphenidate, Drug: Mixed Amphetamine Salts, ER, Drug: placebo | Arm Label: Adderall XR then Focalin XR; Type: EXPERIMENTAL; Interventions: Drug: Dexmethylphenidate, Drug: Mixed Amphetamine Salts, ER, Drug: placebo | Intervention Type: DRUG; Name: Dexmethylphenidate; Assigned to Arm(s): Adderall XR then Focalin XR, Focalin XR then Adderall XR | Intervention Type: DRUG; Name: Mixed Amphetamine Salts, ER; Assigned to Arm(s): Adderall XR then Focalin XR, Focalin XR then Adderall XR | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Adderall XR then Focalin XR, Focalin XR then Adderall XR
D: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC #683864, IND #61010) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Brief Summary: This phase II trial is studying the side effects and how well temsirolimus works in treating patients with refractory or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Options:
A: Arm Label: KU-0059436; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436
B: Arm Label: Treatment (temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: temsirolimus | Intervention Type: DRUG; Name: temsirolimus; Assigned to Arm(s): Treatment (temsirolimus)
C: Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD0530, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: AZD0530; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2, Active Comparator | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2, Active Comparator
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides
Brief Summary: A comparison of intermittent pulsed cyclophosphamide to daily oral cyclophosphamide for the treatment of ANCA-associated systemic vasculitides with kidney involvement.

Performed by the European Vasculitis Study group.


Options:
A: Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Prednisone (and methylprednisolone); Assigned to Arm(s): N/A
B: Arm Label: Placebo plus azathioprine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Azathioprine | Arm Label: Belimumab 10 mg/kg plus azathioprine; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 10 mg/kg, Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo plus azathioprine | Intervention Type: BIOLOGICAL; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus azathioprine | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Belimumab 10 mg/kg plus azathioprine, Placebo plus azathioprine
C: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A
D: Arm Label: A; Type: OTHER; Interventions: Drug: prednisone, methylprednisolone,cyclophosphamides, Drug: Mycophenolate mofetil,methotrexate | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone, Drug: Mycophenolate mofetil,methotrexate | Intervention Type: DRUG; Name: prednisone, methylprednisolone,cyclophosphamides; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Mycophenolate mofetil,methotrexate; Assigned to Arm(s): A, B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides
Brief Summary: A comparison of intermittent pulsed cyclophosphamide to daily oral cyclophosphamide for the treatment of ANCA-associated systemic vasculitides with kidney involvement.

Performed by the European Vasculitis Study group.


Options:
A: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Azathioprine: 2 mg/kg/day; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Intravenous immunoglobulins (human immunoglobulins G); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: azathioprine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.
Brief Summary: The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.


Options:
A: Arm Label: q2 wks; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: q4 wks; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: BIOLOGICAL; Name: pegloticase; Assigned to Arm(s): q2 wks, q4 wks
B: Intervention Type: DRUG; Name: Oxypurinol; Assigned to Arm(s): N/A
C: Arm Label: q2 RCT; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: q4 RCT; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: Placebo in RCT; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Intervention Type: BIOLOGICAL; Name: pegloticase; Assigned to Arm(s): Placebo in RCT, q2 RCT, q4 RCT
D: Arm Label: Febuxostat 40 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol 200 mg or 300 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 40 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol 200 mg or 300 mg QD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.
Brief Summary: The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (for Rilonacept) | Arm Label: Rilonacept 160 mg; Type: EXPERIMENTAL; Interventions: Biological: Rilonacept | Intervention Type: BIOLOGICAL; Name: Rilonacept; Assigned to Arm(s): Rilonacept 160 mg | Intervention Type: OTHER; Name: Placebo (for Rilonacept); Assigned to Arm(s): Placebo
B: Arm Label: Febuxostat 40 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol 200 mg or 300 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 40 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol 200 mg or 300 mg QD
C: Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 120 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol QD
D: Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 120 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 240 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)
Brief Summary: The purpose of this clinical research study is to learn if addition of abatacept is safe and improves the effectiveness of treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and corticosteroids.


Options:
A: Arm Label: Abatacept 30 mg/kg+Corticosteroids+MMF; Type: EXPERIMENTAL; Interventions: Drug: Corticosteroids (prednisone or prednisolone), Drug: Abatacept, Drug: Mycophenolate mofetil (MMF) | Arm Label: Abatacept 10 mg/kg+Corticosteroids+MMF; Type: EXPERIMENTAL; Interventions: Drug: Corticosteroids (prednisone or prednisolone), Drug: Abatacept, Drug: Mycophenolate mofetil (MMF) | Arm Label: Placebo+Corticosteroids+MMF; Type: EXPERIMENTAL; Interventions: Drug: Corticosteroids (prednisone or prednisolone), Drug: Mycophenolate mofetil (MMF) | Arm Label: Abatacept 10mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Intervention Type: DRUG; Name: Corticosteroids (prednisone or prednisolone); Assigned to Arm(s): Abatacept 10 mg/kg+Corticosteroids+MMF, Abatacept 30 mg/kg+Corticosteroids+MMF, Placebo+Corticosteroids+MMF | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept 30 mg/kg+Corticosteroids+MMF | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept 10 mg/kg+Corticosteroids+MMF | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): Abatacept 10 mg/kg+Corticosteroids+MMF, Abatacept 30 mg/kg+Corticosteroids+MMF, Placebo+Corticosteroids+MMF | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept 10mg/kg
B: Arm Label: Human Umbilical Cord derived MSCs; Type: EXPERIMENTAL; Interventions: Biological: Human Umbilical Cord derived MSCs | Arm Label: Cyclophosphamide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide | Intervention Type: BIOLOGICAL; Name: Human Umbilical Cord derived MSCs; Assigned to Arm(s): Human Umbilical Cord derived MSCs | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide
C: Arm Label: Low dose Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Azathioprine, Drug: Methylprednisolone | Arm Label: High Dose Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Azathioprine, Drug: Methylprednisolone | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): High Dose Cyclophosphamide, Low dose Cyclophosphamide | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): High Dose Cyclophosphamide, Low dose Cyclophosphamide | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): High Dose Cyclophosphamide, Low dose Cyclophosphamide
D: Intervention Type: DRUG; Name: Abetimus sodium (LJP 394); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH)
Brief Summary: To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.


Options:
A: Arm Label: Sildenafil High dose; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: Sildenafil Low dose; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: Sildenafil medium dose; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: Sildenafil - Open label Phase; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil High dose | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil Low dose | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil medium dose | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): Sildenafil - Open label Phase
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tadalafil | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): Tadalafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52 Weeks Double Blind Study With 500mcg Roflumilast Once Daily Versus Placebo. Ratio-Study.
Brief Summary: The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: UK-500,001; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52 Weeks Double Blind Study With 500mcg Roflumilast Once Daily Versus Placebo. Ratio-Study.
Brief Summary: The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Roflumilast; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Placebo, Roflumilast
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Daliresp; Type: ACTIVE_COMPARATOR; Interventions: Drug: roflumilast | Intervention Type: DRUG; Name: roflumilast; Assigned to Arm(s): Daliresp | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: A randomized trial comparing radiotherapy with supportive care in patients aged 70 years or older with newly diagnosed, histologically confirmed anaplastic astrocytoma or glioblastoma, and a Karnofsky performance status \> 70.


Options:
A: Arm Label: Cediranib & Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: gefitinib | Arm Label: Cediranbib & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cediranib maleate, Drug: Placebo | Intervention Type: DRUG; Name: cediranib maleate; Assigned to Arm(s): Cediranbib & placebo, Cediranib & Gefitinib | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Cediranib & Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cediranbib & placebo
B: Arm Label: 5-aminolevulinic acid; Type: EXPERIMENTAL; Interventions: Drug: 5-aminolevulinic acid (5-ALA) | Arm Label: Conventional resection; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-aminolevulinic acid (5-ALA); Assigned to Arm(s): 5-aminolevulinic acid
C: Arm Label: Bevacizumab/Irinoecan; Type: EXPERIMENTAL; Interventions: Drug: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures) | Arm Label: Stupp; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temodal/radiotherapy | Intervention Type: DRUG; Name: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures); Assigned to Arm(s): Bevacizumab/Irinoecan | Intervention Type: DRUG; Name: Temodal/radiotherapy; Assigned to Arm(s): Stupp
D: Intervention Type: DRUG; Name: Radiotherapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: A randomized trial comparing radiotherapy with supportive care in patients aged 70 years or older with newly diagnosed, histologically confirmed anaplastic astrocytoma or glioblastoma, and a Karnofsky performance status \> 70.


Options:
A: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy of the partial brain. | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: Radiotherapy of the partial brain.; Assigned to Arm(s): Radiotherapy
B: Intervention Type: DRUG; Name: lomustine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Radiotherapy; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A

Answer: C